Suppr超能文献

印度伤寒疫苗接种的机遇。

Opportunities for Typhoid Vaccination in India.

机构信息

Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.

Department of Community Health, Christian Medical College, Vellore, India.

出版信息

Indian Pediatr. 2019 Jun 15;56(6):453-458.

Abstract

Typhoid fever, an infection with potentially life threatening complications, is responsible for 11 to 21 million illness episodes and 145,000 to 161,000 deaths each year globally. India is a high burden country and also faces the challenge of antimicrobial resistance, which further narrows treatment options. This review analyzes the need for typhoid vaccination in India, and appraises the evidence on efficacy, immunogenicity and cost-effectiveness of currently available typhoid vaccines. In 2018, WHO prequalified the first typhoid conjugate vaccine Vi-TT and recommended it for children aged 6-23 months, along with measles vaccine at 9 or 15 months of age through the expanded programme on immunization. With the high endemicity of typhoid in India and the proven cost-effectiveness of the conjugate vaccine, a roll-out of typhoid vaccine should be considered at the earliest.

摘要

伤寒是一种可能危及生命的传染病,每年在全球造成 1100 万至 2100 万例病例和 14.5 万至 16.1 万人死亡。印度是一个高负担国家,也面临着抗菌药物耐药性的挑战,这进一步缩小了治疗选择。本综述分析了印度伤寒疫苗接种的必要性,并评估了目前可用的伤寒疫苗的疗效、免疫原性和成本效益证据。2018 年,世卫组织预认证了第一种伤寒结合疫苗 Vi-TT,并建议通过扩大免疫规划,在 9 或 15 个月大时与麻疹疫苗一起用于 6-23 个月大的儿童。鉴于印度伤寒的高度流行和结合疫苗的已证实的成本效益,应尽早考虑推出伤寒疫苗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验